Sign in

    Company not found (CBDS)

    Q1 2025 Earnings Summary

    Reported on Jan 1, 1970
    Pre-Earnings PriceN/ADate unavailable
    Post-Earnings PriceN/ADate unavailable
    Price ChangeN/A
    MetricYoY ChangeReason

    Total Revenue

    Down 18% (from $225,131 to $184,473)

    Revenue decreased by $40,658, largely due to intensified competition in the cannabis telemedicine industry that has been negatively impacting demand, a trend observed in previous periods as well.

    Net Loss

    Improved by nearly 52% (from $222,568 to $107,364)

    Net loss narrowed significantly, reflecting successful cost control measures that helped reduce operating and non-operating expenses compared to the previous period, contributing to overall improved profitability performance despite a lower revenue base.

    Operating Expenses

    Down 27% (from $300,904 to $218,581)

    Operating expenses were trimmed by $82,323, building on earlier cost-cutting initiatives; reductions in wages, salaries, and other overheads have helped lower overall expenses in Q1 2025 relative to Q1 2024.

    Wages & Salaries

    Down from $114,071 to $73,390

    Employee costs decreased by approximately $40,681, demonstrating continued aggressive cost management in personnel expenses, a measure already emphasized in earlier periods.

    Cash Flow

    Turned from –$24,744 to +$4,129

    A positive shift in operating cash flow by nearly $28,873 was achieved due to tighter cash management and improved efficiency in operations, marking a reversal of the negative trend observed in Q1 2024.

    Gross Margin

    Improved from 56% to 63%

    Gross margin increased despite a drop in absolute gross profit (from $126,113 to $116,967) because cost of sales declined more than revenue, reflecting enhanced cost leverage and pricing strategies implemented over prior periods.

    Research analysts covering CBDS.